Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

MiRNAs as therapeutics for neurorepair in Multiple Sclerosis

Project description

MiRNAs as a tool to reverse demyelination in multiple sclerosis

Multiple sclerosis (MS) is a chronic disease of the central nervous system characterised by demyelination. The available disease-modifying therapies are unable to induce neurorepair and to prevent the progressive development of disability from neuronal damage. MicroRNAs (miRNAs) are known to be involved in the genes–environment interaction leading to MS. The EU-funded MiRepair project aims to identify miRNAs involved in the demyelination/remyelination processes and to modulate their expression to promote neurorepair in MS. The research will combine previous human miRNA data with robust experimental models to identify miRNAs associated with MS. The goal is to use hydrogel scaffolds in combination with miRNA modulators to enhance remyelination in vivo in animal models.

Objective

I hope to embark my first post-doctoral position, as a MSCA fellow, to identify microRNAs (miRNAs) involved in demyelination/remyelination processes with the final intention of modulating their expression as a therapeutic tool to promote neurorepair in multiple sclerosis (MS). MS is a chronic neurological disease of the central nervous system characterised by primary demyelination. All current disease-modifying therapies are unable to induce neurorepair and to prevent the progressive accumulation of disability from neuronal damage. miRNAs are one epigenetic mechanism involved in the genes-environment interaction that produces the pathology and symptoms in MS. My thesis project consists of describing miRNAs profiles in cerebrospinal fluid and serum of MS patients to exploit their potential role as clinical biomarkers. This project will combine these human miRNA data with robust experimental models in order to identify miRNAs involved in the damage and endogenous repair associated with MS. I will employ ex vivo models to study the biological role of miRNAs during these processes and how their manipulation might enhance neurorepair. The use of hydrogel-scaffolds in combination with miRNA modulators to enhance remyelination will be studied and preclinical MS in vivo models will be used to assess their therapeutic potential. I will work at the “microRNA Inflammation Group” in the Royal College of Surgeons in Ireland (RCSI) under mentorship of Dr Claire McCoy, a leader of MS research in Ireland. Two secondments have been planned in the National University of Ireland, Galway (NUIG) and Queen’s University Belfast (QUB). This fellowship will enable me to upskill in research techniques and expand my transferable skills and competences for a career path for academia or industry in miRNA therapeutics area. This will enhance and contribute to Europe’s competitiveness in R&I supporting European policy objectives as promoting excellence in education and skills development.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2020

See all projects funded under this call

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Net EU contribution
€ 184 590,72
Address
ST STEPHEN GREER 123
D02 YN77 DUBLIN 2
Ireland
Region
Ireland Eastern and Midland Dublin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 184 590,72